• 1
    Burnet FM. Cancer: a biological approach. BMJ. 1957; 1: 779786;841–847.
  • 2
    van der Bruggen P,Traversari C,Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991; 254: 16431647.
  • 3
    Boon T,van der Bruggen P. Human tumor antigens recognized by T lymphocytes. J Exp Med. 1996; 183: 725729.
  • 4
    Dunn GP,Bruce AT,Ikeda H,Old LJ,Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002; 3: 991998.
  • 5
    Nagorsen D,Scheibenbogen C,Marincola FM,Letsch A,Keilholz U. Natural T cell immunity against cancer. Clin Cancer Res. 2003; 9: 42964303.
  • 6
    Galon J,Costes A,Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006; 313: 19601964.
  • 7
    Sato E,Olson SH,Ahn J, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A. 2005; 102: 1853818543.
  • 8
    Ishikawa T,Fujita T,Suzuki Y, et al. Tumor-specific immunological recognition of frameshift-mutated peptides in colon cancer with microsatellite instability. Cancer Res. 2003; 63: 55645572.
  • 9
    Pages F,Berger A,Camus M, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med. 2005; 353: 26542666.
  • 10
    Mapara MY,Sykes M. Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. J Clin Oncol. 2004; 22: 11361151.
  • 11
    Cutler CW,Jotwani R,Pulendran B. Dendritic cells: immune saviors or Achilles' heel? Infect Immun. 2001; 69: 47034708.
  • 12
    Konig R. Interactions between MHC molecules and co-receptors of the TCR. Curr Opin Immunol. 2002; 14: 7583.
  • 13
    Sharpe AH,Abbas AK. T-cell costimulation — biology, therapeutic potential, and challenges. N Engl J Med. 2006; 355: 973975.
  • 14
    Greenfield EA,Nguyen KA,Kuchroo VK. CD28/B7 costimulation: a review. Crit Rev Immunol. 1998; 18: 389418.
  • 15
    Janeway CA. Immunobiology: The Immune System in Health and Disease. 5th ed. New York: Garland; 2001.
  • 16
    Morse MA. Technology evaluation: ipilimumab, Medarex/Bristol-Myers Squibb. Curr Opin Mol Ther. 2005; 7: 588597.
  • 17
    Kwon ED,Qingyong J,Hurwitz AA. Operation enduring costimulation: modulation of B7 receptors to elicit anti-tumor immunity. In: ChenL, ed. The B7-CD28 Family Molecules. New York: Springer; 2003.
  • 18
    Mittler RS,Foell J,McCausland M, et al. Anti-CD137 antibodies in the treatment of autoimmune disease and cancer. Immunol Res. 2004; 29: 197208.
  • 19
    Blank C,Gajewski TF,Mackensen A. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol Immunother. 2005; 54: 307314.
  • 20
    Nam KO,Kang WJ,Kwon BS,Kim SJ,Lee HW. The therapeutic potential of 4–1BB (CD137) in cancer. Curr Cancer Drug Targets. 2005; 5: 357363.
  • 21
    Blank C,Kuball J,Voelkl S, et al. Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int J Cancer. 2006; 119: 317327.
  • 22
    Gajewski TF,Meng Y,Blank C, et al. Immune resistance orchestrated by the tumor microenvironment. Immunol Rev. 2006; 213: 131145.
  • 23
    Peggs KS,Quezada SA,Korman AJ,Allison J. Principles and use of anti-CTLA4 antibody in human cancer. Curr Opin Immunol. 2006; 18: 206213.
  • 24
    Brunet JF,Denizot F,Luciani MF, et al. A new member of the immunoglobulin superfamily—CTLA-4. Nature. 1987; 328: 267270.
  • 25
    Chambers CA,Kuhns MS,Egen JG,Allison JP. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol. 2001; 19: 565594.
  • 26
    Korman AJ,Peggs KS,Allison JP. Checkpoint blockade in cancer immunotherapy. Adv Immunol. 2006; 90: 297339.
  • 27
    Tivol EA,Borriello F,Schweitzer AN,Lynch WP,Bluestone JA,Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 1995; 3: 541547.
  • 28
    Waterhouse P,Penninger JM,Timms E, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science. 1995; 270: 985988.
  • 29
    Kristiansen OP,Larsen ZM,Pociot F. CTLA-4 in autoimmune diseases—a general susceptibility gene to autoimmunity? Genes Immun. 2000; 1: 170184.
  • 30
    Chistiakov DA,Turakulov RI. CTLA-4 and its role in autoimmune thyroid disease. J Mol Endocrinol. 2003; 31: 2136.
  • 31
    Donner H,Braun J,Seidl C, et al. Codon 17 polymorphism of the cytotoxic T lymphocyte antigen 4 gene in Hashimoto's thyroiditis and Addison's disease. J Clin Endocrinol Metab. 1997; 82: 41304132.
  • 32
    Blomhoff A,Lie BA,Myhre AG, et al. Polymorphisms in the cytotoxic T lymphocyte antigen-4 gene region confer susceptibility to Addison's disease. J Clin Endocrinol Metab. 2004; 89: 34743476.
  • 33
    Zalloua PA,Abchee A,Shbaklo H, et al. Patients with early onset of type 1 diabetes have significantly higher GG genotype at position 49 of the CTLA4 gene. Hum Immunol. 2004; 65: 719724.
  • 34
    Vaidya B,Pearce SH,Charlton S, et al. An association between the CTLA4 exon 1 polymorphism and early rheumatoid arthritis with autoimmune endocrinopathies. Rheumatology (Oxford). 2002; 41: 180183.
  • 35
    Sanderson K,Scotland R,Lee P, et al. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol. 2005; 23: 741750.
  • 36
    Faries MB,Hsueh EC,Shu S, et al. Post-vaccination CTLA-4 expression correlates inversely with survival in patients vaccinated with allogeneic melanoma cell vaccine. J Clin Oncol. 2004; 22(14S): 2565.
  • 37
    Korman A,Yellin M,Keler T. Tumor immunotherapy: preclinical and clinical activity of anti-CTLA4 antibodies. Curr Opin Investig Drugs. 2005; 6: 582591.
  • 38
    van Elsas A,Hurwitz AA,Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med. 1999; 190: 355366.
  • 39
    Hurwitz AA,Yu TF,Leach DR,Allison JP. CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc Natl Acad Sci U S A. 1998; 95: 1006710071.
  • 40
    Hurwitz AA,Foster BA,Kwon ED. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res. 2000; 60: 24442448.
  • 41
    Gregor PD,Wolchok JD,Ferrone CR, et al. CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems. Vaccine. 2004; 22: 17001708.
  • 42
    Sutmuller RP,van Duivenvoorde LM,van Elsas A, et al. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med. 2001; 194: 823832.
  • 43
    Demaria S,Kawashima N,Yang AM, et al. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res. 2005; 11: 728734.
  • 44
    Mokyr MB,Kalinichenko T,Gorelik L,Bluestone JA. Realization of the therapeutic potential of CTLA-4 blockade in low-dose chemotherapy-treated tumor-bearing mice. Cancer Res. 1998; 58: 53015304.
  • 45
    Tchekmedyian S,Glasby J,Korman A, et al. MDX-010 (human anti-CTLA4): a phase I trial in malignant melanoma. J Clin Oncol. 2002; 21. Abstract 56.
  • 46
    Davis TA,Tchekmedyian S,Korman A, et al. MDX-010 (human anti-CTLA4): a phase 1 trial in hormone refractory prostate carcinoma (HRPC). Proc Am Soc Clin Oncol 2002; 21. Abstract 74.
  • 47
    Hodi FS,Mihm MC,Soiffer RJ, et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A. 2003; 100: 47124717.
  • 48
    Ribas A,Camacho LH,Lopez-Berestein G, et al. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol. 2005; 23: 89688977.
  • 49
    Gomez-Navarro J,Sharma A,Bozon V, et al. Dose and schedule selection for the anti-CTLA4 monoclonal antibody CP-675,206 in patients (pts) with metastatic melanoma. J Clin Oncol. 2006; 24( 18 suppl): s460. Abstract 8032.
  • 50
    Reuben JM,Lee BN,Li C, et al. Biologic and immunomodulatory events after CTLA-4 blockade with CP-675,206 in patients with advanced malignant melanoma. Cancer. 2006; 106: 24372444.
  • 51
    Bulanhagui CA,Ribas A,Pavlov D, et al. Phase I clinical trials of CP-675,206: tumor responses are sufficient but not necessary for prolonged survival. J Clin Oncol. 2006; 24( 18 suppl). Abstract 8036.
  • 52
    Fischkoff SA,Hersh E,Weber J, et al. Durable responses and long-term progression-free survival observed in a phase II study of MDX-010 alone or in combination with dacarbazine (DTIC) in metastatic melanoma. J Clin Oncol. 2005; 23( 16 suppl). Abstract 7525.
  • 53
    Attia P,Phan GQ,Maker AV, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol. 2005; 23: 60436053.
  • 54
    Phan GQ,Yang JC,Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A. 2003; 100: 83728377.
  • 55
    Maker AV,Phan GQ,Attia P, et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin-2: a phase I/II study. Ann Surg Oncol. 2005; 12: 10051016.
  • 56
    Hamid O,Urba W,Yellin M, et al. Kinetics of response to ipilimumab (MDX-010) in patients with stage III/IV melanoma. J Clin Oncol. 2007; 25( 18 suppl). Abstract 8525.
  • 57
    Weber J,Hersh E,Yellin M, et al. The efficacy and safety of ipilimumab (MDX-010) in subjects with unresectable stage III or IV malignant melanoma. J Clin Oncol. 2007; 25( 18 suppl). Abstract 8523.
  • 58
    Ribas A,Antonia S,Sosman J, et al. Results of a phase II clinical trial of 2 doses and schedules of CP-675,206, an anti-CTLA4 monoclonal antibody in patients with advanced melanoma. J Clin Oncol. 2007; 25( 18 suppl). Abstract 3000.
  • 59
    Gomez-Navarro J,Antonia S,Sosman J, et al. Survival of patients with metastatic melanoma treated with the anti-CTLA4 monoclonal antibody (mAb) CP-675–206 in a phase I/II study. J Clin Oncol. 2007; 25( 18 suppl). Abstract 8524.
  • 60
    Fong L,Kavanagh B,Hou Y, et al. Combination immunotherapy with GM-CSF and CTLA-4 blockade for hormone refractory prostate cancer: balancing the expansion of activated effector and regulatory T cells. J Clin Oncol. 2007; 25( 18 suppl). Abstract 3001.
  • 61
    Gerritsen W,van den Eertwegh AJ,De Gruijl T, et al. Biochemical and immunologic correlates of clinical response in a combination trial of the GM-CSF-gene transduced allogeneic prostate cancer immunotherapy and ipilimumab in patients with metastatic hormone-refractory prostate cancer (mHRPC). J Clin Oncol. 2007; 25( 18 suppl). Abstract 5120.
  • 62
    Small E,Higano C,Tchekmedyian N, et al. Randomized phase II study comparing 4 monthly doses of ipilimumab (MDX-010) as a single agent or in combination with a single dose of docetaxel in patients with hormone-refractory prostate cancer. J Clin Oncol. 2006; 24( 18 suppl). Abstract 4609.
  • 63
    Chung K,Gore I,Fong L, et al. A phase II study of the anti-CTLA4 monoclonal antibody (mAb), CP-675–206, in patients with refractory metastatic adenocarcinoma of the colon or rectum. J Clin Oncol. 2007; 25( 18 suppl). Abstract 3035.
  • 64
    Weber JS,Targan S,Scotland R, et al. Phase II trial of extended dose anti-CTLA-4 antibody ipilimumab (formerly MDX-010) with a multi-peptide vaccine for resected stages IIIC and IV melanoma. J Clin Oncol. 2006; 24( 18 suppl). Abstract 2510.
  • 65
    Beck KE,Blansfield JA,Tran KQ, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol. 2006; 24: 22832289.
  • 66
    Antonia S,Sosman J,Kirkwood JM, et al. Natural history of diarrhea associated with the anti-CTLA-4 monoclonal antibody. J Clin Oncol. 2007; 25( 18 suppl). Abstract 3038.
  • 67
    Blansfield JA,Beck KE,Tran K, et al. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother. 2005; 28: 593598.
  • 68
    Chen B,Phillips J,Greenbaum M, et al. Efficacy of anti-CTLA-4 antibody in the SA1N tumor model when combined with dexamethasone In: American Association for Cancer Research Annual Meeting: Proceedings; 2007 April 14–18; Los Angeles, CA. Philadelphia: AACR; 2007. Abstract 2202.
  • 69
    Maker AV,Yang JC,Sherry RM, et al. Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J Immunother. 2006; 29: 455463.
  • 70
    Takahashi T,Tagami T,Yamazaki S, et al. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med. 2000; 192: 303310.
  • 71
    Maker AV,Attia P,Rosenberg SA. Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J Immunol. 2005; 175: 77467754.
  • 72
    Melero I,Hervas-Stubbs S,Glennie M,Pardoll DM,Chen L. Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer. 2007; 7: 95106.
  • 73
    Ansell SM,Geyer SM,Hurvitz S, et al. Phase I/II study of ipilimumab (MDX-010), an anti-CTLA-4 monoclonal antibody, in patients with follicular non-Hodgkin lymphoma. Blood. 2006; 108( 11 suppl): 772a. Abstract 2729.
  • 74
    Yang JC,Beck KE,Blansfield JA,Tran KQ,Lowry I,Rosenberg SA. Tumor regression in patients with metastatic renal cancer treated with a monoclonal antibody to CTLA4 (MDX-010). J Clin Oncol. 2005; 23( 16 suppl): s166. Abstract 2501.